The comparison of azilsartan and amlodipine for treatment of VEGF receptor-tyrosine kinase inhibitor-induced hypertension in advanced kidney cancer patients
Not Applicable
- Conditions
- VEGFR-TKI-induced hypertension
- Registration Number
- JPRN-UMIN000010940
- Lead Sponsor
- Kanazawa University, 13-1 Takaramachi, Kanazawa
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 10
Inclusion Criteria
Not provided
Exclusion Criteria
1. < 20 year-old 2. Cr>3.0mg/dl or eGFR<15ml/min 3. bilateral renal arterial stenosis or unilateral renal rterial stenosis in solitary kidney 4. allergy to angiotensin 2 receptor blockers or calcium channel blockers and patients who were thought as inadequate for this study by doctor in charge
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The comparison of the efficacy between azilsartan group and amlodipine group
- Secondary Outcome Measures
Name Time Method